Based on the results of this research, we will continue to develop ICG, IRDye800CW and other fluorescent dye-labeled PSMA ligands and plan to develop nuclide and fluorescent dual-modal probes with rapid targeting of prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.